StreetAlpha.app
Home › Stocks › IOVA

Iovance Biotherapeutics, Inc. (IOVA)

Healthcare
$7.53
▼ −0.26%
LAST CLOSE · NOV 17

Iovance Biotherapeutics makes Amtagvi, a personalized cell therapy for advanced melanoma, and sells Proleukin, a related cancer drug. It last closed at $7.53 on Nov 17, down 0.26% on the day. The average 12-month price target from 8 analysts is $14.13 (+87.6% from the last close), with a high of $20.00 and a low of $8.00. Analyst consensus is Strong Buy, based on the latest ratings from 8 firms (6 buy, 2 hold, 0 sell). Over the past 90 days StreetAlpha recorded 1 whale options trade in IOVA, 100% of them bullish and 0% bearish. In the past 30 days there were 4 dark pool prints totaling $1.1M, the largest $352K.

AI Auto Pilots
Is IOVA in one of our four AI portfolios? Sign in free to see

Key Stats

Last 12 months
Results
Revenue
$379.0M
+51.3% vs a year ago
Net income
−$220.5M
−58.2% margin
EPS (diluted)
−$0.49
Free cash flow
−$216.1M
−57.0% margin
Valuation
Market cap
$3.5B
462.7M shares
P/E
–
No P/E while losing money
Price to sales
9.2
Market cap over revenue
Dividend yield
None
No dividend in 12 months
Balance sheet
Cash & equivalents
$57.9M
At Sep 30
Shareholder equity
$812.7M
Shares outstanding
462.7M
At Oct 27
Fiscal year endsDecember
ExchangeNasdaq
Financials history
FY2023: $1.2M$1.2MFY2023FY2024: $164.1M$164.1MFY2024FY2025: $263.5M$263.5MFY2025

From IOVA's SEC filings, latest 10-Q for the period ending Sep 30, 2026 (filed Nov 5). Last 12 months adds up the four latest quarters.

Last report
Nov 5
2026 · next date not on the calendar yet
Consensus EPS forecast
—
 
Year-ago EPS
—
Not on file
Options-implied move
—
 
Analyst consensus
Strong Buy
Based on 8 analyst ratings (90 days)
Loading…

Analyst Ratings & Price Targets

Analyst Ratings →
Consensus · 90 days
Strong Buy
8firms
6 Buy2 Hold0 Sell
Each firm's latest rating on IOVA in the past 90 days
Average 12-month target
$14.13
▲ 87.6% upside

Based on 8 analysts who set a price target on IOVA in the past 90 days. The average target is $14.13, with a high of $20.00 and a low of $8.00, compared with the last close of $7.53.

$2$9$15$21PAST 95 TRADING DAYS12-MONTH TARGETSHIGH $20AVG $14.13LOW $8May 22LAST CLOSE+12 MO$2$9$15$21PAST 95 DAYSTARGETSHIGH $20AVG $14.13LOW $8May 22LAST CLOSE+12 MO
Highest target$20.00
Average target$14.13
Lowest target$8.00
Latest rating changes
BarclaysTarget raised
Nov 6Buy$18 → $19
CitizensTarget raised
Nov 6Buy$8 → $12
UBSTarget raised
Nov 3Hold$7 → $8
BarclaysTarget raised
Oct 13Buy$15 → $18
BairdMaintained
Oct 8Hold$11
DateFirmActionRatingPrice target
Nov 6BarclaysTarget raisedBuy$18 → $19
Nov 6CitizensTarget raisedBuy$8 → $12
Nov 3UBSTarget raisedHold$7 → $8
Oct 13BarclaysTarget raisedBuy$15 → $18
Oct 8BairdMaintainedHold$11
Loading…

Technical Analysis

IOVA · as of the Nov 17 close · updated after every close
Pullback inside a longer uptrend, nearing oversold

The stock is 33% below its 20 day and 50% below its 50 day average. It is 18% above its 200 day average, so the longer trend is still up. Momentum is weak (RSI 32), near oversold. The nearest support is the Pivot at $7.52, and the nearest resistance the Pivot R1 at $7.78.

Short trendBearish
Long trendBullish
MomentumWeak
StretchNear oversold
VolatilityHigh, 11.3%/day
Key levels
$15.3752 week high+104.1%
$11.2950 day average+49.9%
$10.0120 day average+32.9%
$8.91Swing high (Sep 8)+18.3%
$8.64100 day average+14.7%
$7.78Pivot R1+3.3%
$7.53Last close
$7.52Pivot−0.1%
$7.27Pivot S1−3.5%
$6.16200 day average−18.2%
$3.96Swing low (Aug 3)−47.4%
$2.0852 week low−72.4%
Indicators
RSI (14)31.75Weak, oversold below 30Neutral
MACD-1.32Below its signal lineBearish
Stochastic3.9Near the bottom of its rangeOversold
ADX (14)40.2Strong downtrend
Williams %R-93.6Oversold below −80, overbought above −20Oversold
CCI (20)-66.3Oversold below −100, overbought above 100Neutral
Rate of change−14.7%Change over 10 sessionsBearish
ATR (14)$0.85Typical daily range, 11.3% of price
MA 10Below
MA 20Below
MA 50Below
MA 100Below
MA 200Above
What happened before, for IOVA

What happened before

See how IOVA did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record.

November seasonalityHow IOVA usually does this month. See Seasonality

Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.

Seasonality

How IOVA has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2010.

Loading…

See the stocks that usually rise in November →

Whale Options Flow

90D
Total alerts
1
Bullish
1
100%
Bearish
0
0%
Date span
Oct 1 – Oct 1
Loading…

See today’s whale options flow across the market →

Dark Pool

30D
Prints
4
Notional
$1.1M
Largest print
$352K
Loading…

IOVA Institutional Ownership

Full report →
Fund sentiment · Q3 2026
Bullish
Strongly bearishNeutralStrongly bullish
  • ▲189 buying vs 127 selling
  • ▼Held by funds -2.1 pts
  • ▲Funds holding +43
  • ▲Superinvestors: 3 added, 2 cut
  • ▲Put/call 2.45 to 1.10
Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Funds holdingHeld by funds %
Q3 2026This quarterLast quarterChange
Funds holding335292+14.7%
In funds' top 1092+350.0%
Held by funds60.0%62.1%−2.1 pts
New / increased76 / 11341 / 130+10.5%
Reduced / sold out93 / 3464 / 36+27.0%
Put/call ratio1.102.45−55.3%
Top holders, biggest buyers and sellers, 8 quarters of charts and this season's filings so far.See IOVA institutional ownership →

From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.

AI Auto Pilots

Paper trading

StreetAlpha runs four autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether IOVA is in one of them and how their past IOVA trades turned out.

IOVA in the AI portfolios
Loading…

IOVA News Tone and Price

Loading…

Macro & Market News

All StreetAlpha news →

StreetAlpha hasn't covered IOVA in an article yet. Here's the latest on the wider market.

About Iovance Biotherapeutics

Iovance Biotherapeutics develops and sells cell therapies that use a patient's own immune cells to fight solid tumor cancers. Its main product, Amtagvi, is a single, personalized treatment for adults with advanced melanoma who have had prior treatment, and it is given at treatment centers. The company also sells Proleukin, an interleukin-2 product used in the Amtagvi treatment regimen and in other medical uses, through distributors and other clients. Based in San Carlos, California, Iovance serves cancer treatment centers and is developing therapies for other solid tumors.

Headquarters
San Carlos, CA
Founded
2007